ID   4T1
AC   CVCL_0125
SY   4T1-A; 4T1.0; 4T1/WT
DR   BTO; BTO:0004311
DR   CLO; CLO_0001401
DR   EFO; EFO_0002037
DR   MCCL; MCC:0000017
DR   AddexBio; C0006004/13
DR   ATCC; CRL-2539
DR   BCRJ; 0022
DR   BioGRID_ORCS_Cell_line; 1260
DR   BioSample; SAMN11397647
DR   CCRID; 3101MOUSCSP5056
DR   CCRID; 3101MOUTCM32
DR   CCRID; 4201MOU-CCTCC00294
DR   CCRID; 6101MOU-CERC000107
DR   CCTCC; GDC0294
DR   ChEMBL-Cells; CHEMBL3307995
DR   ChEMBL-Targets; CHEMBL612589
DR   CLS; 300300
DR   GEO; GSM1529765
DR   GEO; GSM1529766
DR   GEO; GSM1529767
DR   GEO; GSM1847461
DR   GEO; GSM1847462
DR   KCB; KCB 200967YJ
DR   Lonza; 481
DR   NCBI_Iran; C604
DR   PRIDE; PXD013948
DR   PRIDE; PXD016112
DR   PRIDE; PXD021413
DR   PRIDE; PXD024762
DR   PRIDE; PXD027822
DR   PubChem_Cell_line; CVCL_0125
DR   Ubigene; YC-B004
DR   Wikidata; Q42802273
RX   PubMed=10411109;
RX   PubMed=26857856;
RX   PubMed=27177471;
RX   PubMed=31220119;
WW   https://en.wikipedia.org/wiki/4T1
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/4/cell-lines-detail-66.html
CC   Characteristics: Metastatic.
CC   Characteristics: Widely used model in cancer research due to its high similarity to human breast cancer. The tumor growth and metastatic spread of 4T1 cells closely mimic the behavior of human breast cancer. The 4T1 cell line is considered an animal model for stage IV human breast cancer, as it is able to spontaneously metastasize in both post-operative and non-surgical models (CLS=300300).
CC   Doubling time: 12.6 hours (ATCC=CRL-2539).
CC   Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Mammary gland; UBERON=UBERON_0001911.
CC   Breed/subspecies: BALB/cfC3H.
ST   Source(s): PubMed=31220119; Ubigene
ST   Mouse STR 1-1: 15,16
ST   Mouse STR 1-2: 17
ST   Mouse STR 11-2: 18,19,20
ST   Mouse STR 12-1: 16
ST   Mouse STR 13-1: 16.2
ST   Mouse STR 15-3: 22.3
ST   Mouse STR 17-2: 15
ST   Mouse STR 18-3: 18,19
ST   Mouse STR 19-2: 13
ST   Mouse STR 2-1: 16,17
ST   Mouse STR 3-2: 14,15
ST   Mouse STR 4-2: 21.3
ST   Mouse STR 5-5: 14
ST   Mouse STR 6-4: 18
ST   Mouse STR 6-7: 12
ST   Mouse STR 7-1: 25.2
ST   Mouse STR 8-1: 13
ST   Mouse STR X-1: 25
DI   NCIt; C21678; Malignant neoplasms of the mouse mammary gland
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_W343 ! 410.4
SX   Female
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 31
//
RX   PubMed=10411109; DOI=10.1023/A:1006689719505;
RA   Lelekakis M., Moseley J.M., Martin T.J., Hards D., Williams E., Ho P.,
RA   Lowen D., Javni J., Miller F.R., Slavin J., Anderson R.L.;
RT   "A novel orthotopic model of breast cancer metastasis to bone.";
RL   Clin. Exp. Metastasis 17:163-170(1999).
//
RX   PubMed=26857856; DOI=10.1007/s13577-015-0127-1;
RA   Abe H., Wada H., Baghdadi M., Nakanishi S., Usui Y., Tsuchikawa T.,
RA   Shichinohe T., Hirano S., Seino K.-i.;
RT   "Identification of a highly immunogenic mouse breast cancer sub cell
RT   line, 4T1-S.";
RL   Hum. Cell 29:58-66(2016).
//
RX   PubMed=27177471; DOI=10.1016/j.canlet.2016.05.005;
RA   Sasaki S.-i., Baba T., Nishimura T., Hayakawa Y., Hashimoto S.-i.,
RA   Gotoh N., Mukaida N.;
RT   "Essential roles of the interaction between cancer cell-derived
RT   chemokine, CCL4, and intra-bone CCR5-expressing fibroblasts in breast
RT   cancer bone metastasis.";
RL   Cancer Lett. 378:23-32(2016).
//
RX   PubMed=31220119; DOI=10.1371/journal.pone.0218412;
RA   Almeida J.L., Dakic A., Kindig K., Kone M., Letham D.L.D., Langdon S.,
RA   Peat R., Holding-Pillai J., Hall E.M., Ladd M., Shaffer M.D., Berg H.,
RA   Li J.-L., Wigger G., Lund S., Steffen C.R., Fransway B.B., Geraghty B.,
RA   Natoli M., Bauer B.A., Gollin S.M., Lewis D.W., Reid Y.A.;
RT   "Interlaboratory study to validate a STR profiling method for
RT   intraspecies identification of mouse cell lines.";
RL   PLoS ONE 14:E0218412-E0218412(2019).
//